Mode
Text Size
Log in / Sign up
Phase 3 N=500 Randomized Quadruple-blind Treatment

High-dose Erythropoietin for Asphyxia and Encephalopathy

Neonatal Encephalopathy · Birth Asphyxia

Enrolled (actual)
500
Serious AEs
48.6%
Results posted
Jan 2023
Primary outcome: Primary: Number of Participants With Death or Neurodevelopmental Impairment — 126; 110 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Normal saline placebo (Drug); Erythropoietin (Drug)
Age
Pediatric
Sex
All
Sponsor
University of California, San Francisco
Primary completion
Oct 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Death or Neurodevelopmental Impairment
126; 110
SECONDARY
Number of Participants With Cerebral Palsy (CP) and Number of Participants With Each Type of Cerebral Palsy (CP), Determined Using a Standardized Neurologic Examination
176; 173; 9; 6; 3; 2
SECONDARY
Number of Participants With Each Level of Gross Motor Function, Determined Using the GMFCS
186; 178; 6; 6; 4; 6
SECONDARY
Bayley III Cognitive Score
89.1; 89.5
SECONDARY
Bayley III Language Score
87.9; 86.7
SECONDARY
Number of Participants With Epilepsy
5; 4
SECONDARY
Number of Participants With Behavioral Abnormalities Determined by the Externalizing Score of the Child Behavior Checklist
15; 3

Summary

Hypoxic-ischemic encephalopathy (HIE) occurs when a baby gets reduced blood flow and oxygen to the brain near the time of birth. This results in death or neurologic disabilities including cerebral palsy and cognitive impairment in up to half of affected infants. This clinical trial will determine if the drug erythropoietin (Epo) added to hypothermia (usual therapy) will improve outcomes for infants suffering from HIE.

Eligibility Criteria

Inclusion Criteria

  • ≥ 36 weeks of gestational age
  • Receiving active or passive whole body cooling/hypothermia since 65.0%)
  • Parents/legal guardians with diminished capacity and autonomy
  • Infant is participating or intends to participate in another interventional study during the birth hospitalization (note: does not include observational studies)
  • Sentinel event and encephalopathy occurred only after birth
  • Unable to consent in primary language of parent(s)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02811263). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search